Today: 20 March 2026
Subscribe
Browse Category

NYSE:BHVN 13 August 2025 - 3 November 2025

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Ltd. shares dropped over 20% in pre-market trading Nov. 3, falling to about $13.40 after closing at $17.20 on Oct. 31. The decline comes ahead of an FDA decision on troriluzole, expected in Q4 2025. The stock is down roughly 66% year-over-year, far underperforming biotech peers. Biohaven reported $408 million in cash mid-2025 but posted a $198 million net loss in Q2.
3 November 2025
·
Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

The FDA approved brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis, affecting about 500,000 Americans. Novartis reported positive Phase 3 results for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. Biohaven’s OCD drug troriluzole failed in late-stage trials. Cardinal Health will acquire Solaris Health for $1.9 billion in cash.
13 August 2025
···

Stock Market Today

  • Nevada Temporarily Bans Prediction Market Firm Kalshi Over Gaming License Dispute
    March 20, 2026, 2:30 PM EDT. Kalshi, a prediction markets platform offering event-based contracts on sports, elections, and entertainment, was temporarily banned in Nevada by a 14-day restraining order from the First Judicial District Court. The ruling prohibits Kalshi from operating its derivatives exchange without a gaming license, marking the first state-level forced cessation for the company. The ban follows earlier Nevada cease-and-desist actions and precedes a likely extension through the legal case, said gaming attorney Daniel Wallach. The dispute comes amid mounting regulatory scrutiny nationally, including criminal charges from Arizona and ongoing battles in multiple states. Kalshi contends its sports contracts are financial swaps, not gambling, a view supported by the federal Commodity Futures Trading Commission, which claims jurisdiction over these markets. This case highlights tensions between state gambling laws and federally regulated prediction markets.
Go toTop